Meningococcal Quadrivalent (Serogroups A, C, W135 and Y) Tetanus Toxoid Conjugate Vaccine (Nimenrix™)

MenACWY-TT vaccine for active immunization against invasive meningococcal disease

(2012) Vassiliki Papaevangelou et al.   Expert Review of Vaccines

The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine

(2012) Ghassan Dbaibo et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Increase of meningococcal serogroup Y cases in Europe: A reason for concern?

(2012) Michael Bröker et al.   Human Vaccines & Immunotherapeutics

An evaluation of emerging vaccines for childhood meningococcal disease

(2011) Debajeet Choudhuri et al.   BMC PUBLIC HEALTH

Changing epidemiology of meningococcal disease in Europe from the mid-20th to the early 21st Century

(2011) Paula Kriz et al.   Expert Review of Vaccines

Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents

(2011) Christopher J. Gill et al.   Human vaccines & immunotherapeutics

Cost impact of complications in meningococcal disease: Evidence from a United States managed care population

(2011) Keith L. Davis et al.   Human vaccines & immunotherapeutics

Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults

(2011) Nancy Bermal et al.   Human vaccines & immunotherapeutics

Bacterial Meningitis in the United States, 1998–2007

(2011) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenicity of a Single Dose of Tetravalent Meningococcal Serogroups A, C, W-135, and Y Conjugate Vaccine Administered to 2- to 10-year-olds Is Noninferior to a Licensed-ACWY Polysaccharide Vaccine With an Acceptable Safety Profile

(2011) Ziad A. Memish et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal ACWY Tetanus Toxoid Conjugate Vaccine in Healthy Adolescents and Young Adults 10 to 25 Years of Age

(2011) Roger Baxter et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A Randomized Trial to Assess Safety and Immunogenicity of Alternative Formulations of a Quadrivalent Meningococcal (A, C, Y, and W-135) Tetanus Protein Conjugate Vaccine in Toddlers

(2011) Jodie McVernon et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix™ hexa is immunogenic, with an acceptable safety profile in 12–23-month-old children

(2011) Markus Knuf et al.   VACCINE

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: An open, randomized controlled trial

(2011) Timo Vesikari et al.   VACCINE

A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial

(2011) Lars Østergaard et al.   VACCINE

Meningococcal Quadrivalent (Serogroups A, C, W135, and Y) Conjugate Vaccine (Menveo®)

(2010) Emma D. Deeks   BIODRUGS

Updated Postlicensure Surveillance of the Meningococcal C Conjugate Vaccine in England and Wales: Effectiveness, Validation of Serological Correlates of Protection, and Modeling Predictions of the Duration of Herd Immunity

(2010) H. Campbell et al.   Clinical and Vaccine Immunology

Epidemiological Profile of Meningococcal Disease in the United States

(2010) Lee H. Harrison   CLINICAL INFECTIOUS DISEASES

Optimizing Protection Against Meningococcal Disease

(2010) Keith S. Reisinger et al.   CLINICAL PEDIATRICS

Advances in the Development of Vaccines againstNeisseria meningitidis

(2010) Lionel K.K. Tan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Changes inNeisseria meningitidisDisease Epidemiology in the United States, 1998–2007: Implications for Prevention of Meningococcal Disease

(2009) Amanda C. Cohn et al.   CLINICAL INFECTIOUS DISEASES

Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs

(2009) Caroline L Trotter et al.   Expert Review of Vaccines

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: A persistent problem with an imminent solution

(2009) F. Marc LaForce et al.   VACCINE

Chemistry of a new investigational quadrivalent meningococcal conjugate vaccine that is immunogenic at all ages

(2009) Michael Bröker et al.   VACCINE

Global epidemiology of meningococcal disease

(2009) Lee H. Harrison et al.   VACCINE

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

(2009) M. Knuf et al.   VACCINE

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

(2008) Lars Østergaard et al.   VACCINE